These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26008804)

  • 41. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
    Dekkers CCJ; Sjöström CD; Greasley PJ; Cain V; Boulton DW; Heerspink HJL
    Diabetes Obes Metab; 2019 Dec; 21(12):2667-2673. PubMed ID: 31407856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
    Merovci A; Mari A; Solis-Herrera C; Xiong J; Daniele G; Chavez-Velazquez A; Tripathy D; Urban McCarthy S; Abdul-Ghani M; DeFronzo RA
    J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin.
    Mori H; Okada Y; Kawaguchi M; Tanaka Y
    J UOEH; 2016 Jun; 38(2):149-53. PubMed ID: 27302728
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of dapagliflozin on renal function in patients with type 2 diabetes.
    Kohan DE; Fioretto P; Johnsson K; Parikh S; Ptaszynska A; Ying L
    J Nephrol; 2016 Jun; 29(3):391-400. PubMed ID: 26894924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
    Papadopoulou E; Theodorakopoulou MP; Loutradis C; Tzanis G; Tzatzagou G; Kotsa K; Zografou I; Tsapas A; Karagiannis A; Sarafidis P
    Am J Hypertens; 2021 Apr; 34(4):404-413. PubMed ID: 33277990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.
    Toto RD; Goldenberg R; Chertow GM; Cain V; Stefánsson BV; Sjöström CD; Sartipy P
    J Diabetes Complications; 2019 Oct; 33(10):107402. PubMed ID: 31375422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature.
    Solini A; Seghieri M; Giannini L; Biancalana E; Parolini F; Rossi C; Dardano A; Taddei S; Ghiadoni L; Bruno RM
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4253-4263. PubMed ID: 31162549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dapagliflozin Attenuates Sympathetic and Pressor Responses to Stress in Young Prehypertensive Spontaneously Hypertensive Rats.
    Kim HK; Ishizawa R; Fukazawa A; Wang Z; Bezan Petric U; Hu MC; Smith SA; Mizuno M; Vongpatanasin W
    Hypertension; 2022 Aug; 79(8):1824-1834. PubMed ID: 35652337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors.
    Ghanim H; Batra M; Green K; Hejna J; Abuaysheh S; Makdissi A; Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2021 Jul; 23(7):1614-1623. PubMed ID: 33729664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research-to-practice" project from the diabetes collaborative registry.
    Arnold SV; Seman L; Tang F; Peri-Okonny PA; Ferdinand KC; Mehta SN; Goyal A; Sperling LS; Kosiborod M
    Diabetes Obes Metab; 2019 Feb; 21(2):393-396. PubMed ID: 30136353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes.
    Lee JY; Kim G; Kim SR; Lee YH; Lee BW; Cha BS; Kang ES
    Diabetes Metab; 2017 Apr; 43(2):191-194. PubMed ID: 28089373
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension.
    Hao Z; Sun Y; Wen Y; Cui L; Li G; Liu Y
    Med Sci Monit; 2020 Oct; 26():e925987. PubMed ID: 33010148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus.
    Hidalgo Santiago JC; Maraver Delgado J; Cayón Blanco M; López Saez JB; Gómez-Fernández P
    Med Clin (Barc); 2020 Mar; 154(5):171-174. PubMed ID: 31420083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial.
    Díaz-Cruz C; González-Ortiz M; Rosales-Rivera LY; Patiño-Laguna AJ; Ramírez-Rodríguez ZG; Díaz-Cruz K; Martínez-Abundis E
    Blood Press Monit; 2020 Dec; 25(6):346-350. PubMed ID: 32815921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dapagliflozin in young people with type 2 diabetes.
    Tommerdahl KL; Nelson RG; Bjornstad P
    Lancet Diabetes Endocrinol; 2022 May; 10(5):303-304. PubMed ID: 35378070
    [No Abstract]   [Full Text] [Related]  

  • 58. Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?
    Engeli S; Jordan J
    Curr Hypertens Rep; 2013 Oct; 15(5):470-4. PubMed ID: 23933756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
    Breder I; Wolf VLW; Soares AAS; de Carvalho LSF; Kimura-Medorima ST; Cintra RM; Barreto J; Munhoz DB; Cunha JS; Bonilha I; Coelho-Filho OR; Quinaglia T; Nadruz W; Guerra-Junior G; Muscelli E; Sposito AC;
    Diabetes Metab; 2022 Mar; 48(2):101304. PubMed ID: 34808345
    [No Abstract]   [Full Text] [Related]  

  • 60. American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA).
    Lam S
    Drugs Today (Barc); 2016 Jun; 52(6):361-6. PubMed ID: 27458613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.